Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Anastasiia V. Sadybekov"'
Autor:
Arman A. Sadybekov, Rebecca L. Brouillette, Egor Marin, Anastasiia V. Sadybekov, Aleksandra Luginina, Anastasiia Gusach, Alexey Mishin, Élie Besserer-Offroy, Jean-Michel Longpré, Valentin Borshchevskiy, Vadim Cherezov, Philippe Sarret, Vsevolod Katritch
Publikováno v:
Biomolecules, Vol 10, Iss 12, p 1634 (2020)
Cysteinyl leukotriene G protein-coupled receptors, CysLT1R and CysLT2R, regulate bronchoconstrictive and pro-inflammatory effects and play a key role in allergic disorders, cardiovascular diseases, and cancer. CysLT1R antagonists have been widely use
Externí odkaz:
https://doaj.org/article/f10a2b76089f4d51a6bf3e664058debc
Publikováno v:
Nature. 616:673-685
Autor:
Arman A. Sadybekov, Anastasiia V. Sadybekov, Yongfeng Liu, Christos Iliopoulos-Tsoutsouvas, Xi-Ping Huang, Julie Pickett, Blake Houser, Nilkanth Patel, Ngan K. Tran, Fei Tong, Nikolai Zvonok, Manish K. Jain, Olena Savych, Dmytro S. Radchenko, Spyros P. Nikas, Nicos A. Petasis, Yurii S. Moroz, Bryan L. Roth, Alexandros Makriyannis, Vsevolod Katritch
Publikováno v:
Nature
Structure-based virtual ligand screening is emerging as a key paradigm for early drug discovery owing to the availability of high-resolution target structures(1-4) and ultra-large libraries of virtual compounds(5,6). However, to keep pace with the ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6cb628454a81cf54d8ee8f1bed3cf87
https://europepmc.org/articles/PMC9763054/
https://europepmc.org/articles/PMC9763054/
Autor:
Arman A, Sadybekov, Anastasiia V, Sadybekov, Yongfeng, Liu, Christos, Iliopoulos-Tsoutsouvas, Xi-Ping, Huang, Julie, Pickett, Blake, Houser, Nilkanth, Patel, Ngan K, Tran, Fei, Tong, Nikolai, Zvonok, Manish K, Jain, Olena, Savych, Dmytro S, Radchenko, Spyros P, Nikas, Nicos A, Petasis, Yurii S, Moroz, Bryan L, Roth, Alexandros, Makriyannis, Vsevolod, Katritch
Publikováno v:
Nature. 601(7893)
Structure-based virtual ligand screening is emerging as a key paradigm for early drug discovery owing to the availability of high-resolution target structures